Cogent Biosciences Net Income From Continuing Ops Over Time
| COGT Stock | USD 36.53 0.19 0.52% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cogent Biosciences Performance and Cogent Biosciences Correlation. Is there potential for Biotechnology market expansion? Will Cogent introduce new products? Factors like these will boost the valuation of Cogent Biosciences. Projected growth potential of Cogent fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Cogent Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Cogent Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cogent Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Cogent Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cogent Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cogent Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cogent Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Cogent Biosciences and related stocks such as Arcus Biosciences, Immunitybio, and Denali Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RCUS | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (53.1 M) | (49.6 M) | (84.7 M) | (122.9 M) | 52.8 M | (267 M) | (307 M) | (284 M) | (255.6 M) | (242.8 M) |
| IBRX | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (160.2 M) | (92.4 M) | (349.8 M) | (417.3 M) | (458.8 M) | (413.6 M) | (372.3 M) | (390.9 M) |
| DNLI | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (86.7 M) | (88.2 M) | (36.2 M) | (197.6 M) | 72.8 M | (290.6 M) | (326 M) | (124.4 M) | (422.8 M) | (380.5 M) | (361.5 M) |
| GLPG | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (37.3 M) | (194.3 M) | 54 M | (115.7 M) | (29.3 M) | 149.8 M | (311 M) | (125.4 M) | (218 M) | (153.1 M) | (1.3 M) | (1.2 M) | (1.2 M) |
| AGIO | (39.4 M) | (39.4 M) | (39.4 M) | (39.4 M) | (53.5 M) | (117.7 M) | (198.5 M) | (314.7 M) | (346 M) | (411.5 M) | (309.5 M) | (356.5 M) | (231.8 M) | (352.1 M) | 673.7 M | 774.8 M | 813.5 M |
| VRDN | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (32.7 M) | (41.9 M) | (110.7 M) | (79.6 M) | (130.1 M) | (216.7 M) | (269.9 M) | (243 M) | (230.8 M) |
| RXRX | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (61.9 M) | (87 M) | (186.5 M) | (239.5 M) | (292.6 M) | (463.7 M) | (417.3 M) | (396.4 M) |
Cogent Biosciences and related stocks such as Arcus Biosciences, Immunitybio, and Denali Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Cogent Biosciences | COGT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 275 Wyman Street, |
| Exchange | NASDAQ Exchange |
USD 36.53
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.